
|Articles|May 27, 2004
Docetaxel is approved for advanced prostate Ca
Docetaxel (Taxotere) has been approved by the FDA for the treatment of hormone-refractory metastatic prostate cancer when used in combination with prednisone.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
NDV-01 produces robust 9-month results in high-risk NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
5


















